Whereas timely and full reperfusion is mandatory to salvage myocardium from impending infarction, reperfusion also adds a separate component of reperfusion injury on top of the preceding ischaemic injury and thus contributes to final infarct size. Ischaemic pre-conditioning, i.e. brief cycles of coronary occlusion and reperfusion before the sustained index ischemia which causes infarction, reduces infarct size. 3 However, ischaemic pre-conditioning can be used only in elective coronary interventions and is therefore more of paradigmatic value to highlight molecular self-defense mechanisms rather than of practical clinical value. 4 Ischaemic post-conditioning, i.e. brief cycles of coronary re-occlusion and reperfusion at the immediate onset of reperfusion, reduces infarct size and thus by its very nature establishes the existence of irreversible reperfusion injury. 5 Ischaemic post-conditioning has reduced infarct size in many experimental studies and also in a number of, but not all clinical studies in patients with acute myocardial infarction. So far, however, there is no clinical study which has demonstrated better clinical outcome as the primary endpoint of ischaemic post-conditioning 4, 6 The major disadvantage of ischaemic post-conditioning is the further manipulation of the atherosclerotic culprit lesion which may induce coronary microembolization and additional myocardial damage. 7 Remote ischaemic conditioning, i.e. brief cycles of ischaemia/reperfusion remote from the heart, e.g. by inflation/deflation of a blood pressure cuff on the arm or leg, is safer and also reduces infarct size in experimental studies and in most of the available clinical studies in patients with reperfused acute myocardial infarction. 8 Again, however, evidence for a better clinical outcome as primary endpoint of remote ischaemic conditioning is still lacking. Many signalling steps and molecules of ischaemic conditioning strategies have been identified in experimental studies, 9 but-after some promising smaller proof-of-concept studies for e.g. cyclosporine A, metoprolol or exenatide-no pharmacological intervention at reperfusion has yet unequivocally reduced infarct size and improved clinical outcome for patients with acute myocardial infarction ( Figure 1 ) .
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Reperfusion injury becomes not only manifest as extended infarct size but also as damage to the coronary microcirculation, resulting ultimately in no-reflow which is associated with worse prognosis. Reperfusion injury to the myocardium and to the coronary microcirculation are closely related but probably mechanistically distinct. Coronary microvascular reperfusion injury includes edema, impaired coronary vasomotion, leukocyte adherence and extravasation, intravascular platelet and erythrocyte aggregates, and ultimately capillary destruction and hemorrhage. 10 Some experimental and clinical studies have demonstrated attenuated coronary microvascular injury with ischaemic conditioning strategies and pharmacological interventions, but so far there is no established therapy to reduce coronary microvascular obstruction in patients with reperfused acute myocardial infarction. The translation of cardioprotective strategies from experimental studies to the clinical situation of patients undergoing primary PCI for acute myocardial infarction has been difficult and mostly not successful so far. Many reasons have contributed to such failure of translation, 11 including lack of robust preclinical data from animal models with advanced age, co-morbidities and co-medications, 12,13 lack of robust preclinical data on more long-term outcome such as remodeling and heart failure development, lack of adequate phase II dosing and timing studies after promising proof-of-concept studies but before larger phase III clinical outcome studies, lack of focus on patients with the greatest need of cardioprotection, e.g. with large anterior infarcts, and lack of focus on patients who come in early enough after their symptom onset to truly benefit from 
